ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
4615 articles about ACCESSWIRE
-
Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollar
10/1/2020
Nascent Biotech, Inc. Announced that It has continued to reduce its liabilities through stock conversion and payment of accounts payable and accrued liabilities.
-
ITOCO Completes Blockchain Smart Contract for Immutable Virus Test Result Verification System
10/1/2020
ITOCO INC. has successfully completed and deployed the blockchain portion of its patent-pending Immutable Virus Test Result Verification System to the Ethereum Ropsten test network.
-
Havn Life joins UK Psychedelics Working Group with Leading International Scientists
10/1/2020
The Working Group Consists of Over 35 Academics, Researchers, and Policy Specialists From Four Countries
-
Halberd COVID-19 Preventative Nasal Spray Provisional Patent Application Filed
10/1/2020
Halberd Corporation announced they have obtained world-wide license to a provisional patent application covering a nasal spray to be used as a prevention measure against coronavirus.
-
Theralase Announces Warrant Extension
9/30/2020
Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share.
-
DECN Signs Agreement With US-Based Laboratory as Testing Partner for Genviro! Saliva Swift Kit Testing for Additional FDA, EU CE Mark and Russian Federation Submissions
9/30/2020
FDA & CLIA certified laboratory will begin the testing of the Genviro! 10.5 Sec. Saliva Swift Kit, with full results expected to be reported to regulators in USA, EU and Russian Federation, and will also be included in the Genviro! Swift package inserts
-
Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease
9/30/2020
Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program
-
U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments
9/30/2020
U.S. Stem Cell, Inc. , is pleased to announce that oral arguments for the companys court case USA v. U.S. Stem Cell Clinic, et al has been set for the docket beginning January 11, 2021.
-
Ovation Science to Present at the Virtual Gravitas Securities Healthcare Investor Day, Thursday, Oct 1st at 3:45pm EST
9/30/2020
Ovation Science Inc. is pleased to announce it will be participating in the Gravitas Healthcare Investor Day taking place Thursday, October 1st, 2020 virtually.
-
Hemogenyx Pharmaceuticals PLC Announces Interim Results for the Period Ended 30 June 2020
9/30/2020
Hemogenyx Pharmaceuticals plc, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2020.
-
Pharnext to Host Research and Development Day on October 13, 2020
9/29/2020
Pharnext SA announced that it will host a research and development day focused on the company's development efforts related to its lead asset, PXT3003, in Charcot-Marie-Tooth disease type 1A on Tuesday, October 13, 2020, from 8:00 - 10:30 a.m. ET / 2:00 - 4:30 p.m. CET.
-
Havn Life Sciences Inc. Reports Q1 Financial Statements
9/29/2020
Havn Life Sciences Inc., is pleased to announce Its financial results for the three month period ended July 31, 2020.
-
CureVac: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate
9/29/2020
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV.
-
PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials
9/29/2020
PainReform Ltd.today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain.
-
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
9/29/2020
Hepion Pharmaceuticals, Inc. today announced that Dr. Robert Foster, will present virtually at the H.C. Wainwright 4 th Annual NASH Conference on Monday, October 5, 2020 at 4:00 p.m. E.T.
-
Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Filing of U.S. Patent Application for a System to Neutralize Pathogens on Physical Surfaces
9/29/2020
Applied UV, Inc. today announced that its subsidiary, SteriLumen, Inc. ("SteriLumen"), has filed a patent application with the U.S. Patent and Trademark Office ("USPTO") pertaining to a system to neutralize pathogens on physical surfaces.
-
Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
9/29/2020
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Assure COVID-19 IgG/IgM Rapid Test Device.
-
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs
9/29/2020
Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications
-
SphingoTec GmbH: SphingoTec, BHR Pharmaceuticals Ink Agreement for Distribution of SphingoTec's Acute Care Portfolio in the UK and Ireland
9/29/2020
BHR Pharmaceuticals Ltd and SphingoTec GmbH announced that they have signed a distribution agreement for the commercialization of SphingoTec's portfolio of diagnostics solutions in acute and critical care in UK and Ireland.
-
Imagin Medical to Host Kol Webcast Event on October 29, 2020
9/29/2020
Imagin Medical (CSE:IME)today announced that it will host a virtual investor event with Key Opinion Leaders to highlight the game-changing potential of the i/Blue Imaging System on Thursday, October 29, 2020 at 12:00 pm Eastern Daylight Time.